Compare Quest Diagnostics Inc (DGX) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs JPMorgan Ultra Short Income ETF — how do they compare? Quest Diagnostics Inc trades at $204.84 (market cap $22.80B), while JPMorgan Ultra Short Income ETF trades at $50.49. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while JPMorgan Ultra Short Income ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| DGX | JPST | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.02 | $50.78 |
52-Week Low | $166.42 | $50.40 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
JPST trades at $50.44, down 0.02% with a bearish technical signal from moving averages. The ETF focuses on high-quality, short-term bonds, offering monthly dividends and capital preservation. Recent news highlights strong institutional inflows and its role as a cash alternative in volatile markets. Technical indicators show neutral oscillators but overall bearish momentum, with support and resistance clustered around $50.
Outlook remains stable for income-focused investors seeking low duration risk, though rising Treasury yields pose a headwind. Key risks include interest rate sensitivity and credit spread changes. Institutional ownership trends indicate growing advisor interest, supporting its defensive profile in uncertain rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
